KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Treasury Shares (2016 - 2025)

Sarepta Therapeutics (SRPT) has 13 years of Treasury Shares data on record, last reported at $650876.0 in Q3 2025.

  • For Q3 2025, Treasury Shares changed N/A year-over-year to $650876.0; the TTM value through Sep 2025 reached $650876.0, changed N/A, while the annual FY2023 figure was $2.2 million, 22.46% up from the prior year.
  • Treasury Shares reached $25.3 million in Q3 2025 per SRPT's latest filing, roughly flat from $25.3 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.2 million in Q4 2023 and bottomed at -$651000.0 in Q2 2025.
  • Average Treasury Shares over 4 years is $1.1 million, with a median of $1.3 million recorded in 2021.
  • Peak YoY movement for Treasury Shares: surged 39.4% in 2021, then grew 22.46% in 2023.
  • A 4-year view of Treasury Shares shows it stood at $1.3 million in 2021, then skyrocketed by 38.59% to $1.8 million in 2022, then grew by 22.46% to $2.2 million in 2023, then plummeted by 70.95% to $650876.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $650876.0 in Q3 2025, -$651000.0 in Q2 2025, and $2.2 million in Q4 2023.